Dergiler / Acta Orthopaedica et Traumatologica Turcica / 2015 / Cilt: 49 - Sayı: 2

Effects of salmon calcitonin treatment on serum and synovial fluid bone formation and resorption markers in osteoporosis patients

Sayfa
160–165
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Advanced studies are needed to evaluate the mechanisms by which this takes place, and to explain the relationship between osteoporosis and articular cartilage metabolism

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: This study aimed to evaluate the effects of salmon calcitonin, and calcium and vitamin D treatment on bone mineral density, serum and synovial fluid bone formation and resorption markers in patients with osteoporosis.Methods: The study was completed with twenty-five osteoporosis patients divided into two groups: The 15 patients comprising Group I (1 male and 14 females; mean age: 67.0±12.0) were administered calcitonin treatment in addition to calcium and vitamin D.
📊
Temel Bulgular & Veri:The 10 patients in Group II (3 males and 7 females; mean age 68.0±16.0) were administered calcium and vitamin D only.
💡
Sonuç & Katkı:Advanced studies are needed to evaluate the mechanisms by which this takes place, and to explain the relationship between osteoporosis and articular cartilage metabolism
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: This study aimed to evaluate the effects of salmon calcitonin, and calcium and vitamin D treatment on bone mineral density, serum and synovial fluid bone formation and resorption markers in patients with osteoporosis.Methods: The study was completed with twenty-five osteoporosis patients divided into two groups: The 15 patients comprising Group I (1 male and 14 females; mean age: 67.0±12.0) were administered calcitonin treatment in addition to calcium and vitamin D. The 10 patients in Group II (3 males and 7 females; mean age 68.0±16.0) were administered calcium and vitamin D only. Serum and synovial fluid calcium phosphorus, alkaline phosphatase, calcitonin, C-telopeptide (CTx), N-telopeptide (NTx) and sialoprotein levels, and bone densitometries were determined at the beginning and at the end of one year of treatment.Results: In the calcitonin and calcium and vitamin D treatment group (Group I), femoral neck density scores were decreased and vertebrae scores were increased after one-year treatment. Both scores were increased in the non-calcitonin group (Group II). In Group I, synovial fluid levels of calcitonin, sialoprotein and NTx were decreased, and synovial fluid CTx levels showed no change. The only decrease that was statistically significant was that in calcitonin levels. In Group II, synovial fluid calcitonin levels were decreased, synovial fluid CTx levels were increased and synovial fluid NTx and sialoprotein level were unchanged. These changes were not statistically significant. Serum changes in the parameters were not statistically significant in either group.Conclusion: In osteoporosis, salmon calcitonin treatment affects synovial fluid bone formation and absorption marker levels. Advanced studies are needed to evaluate the mechanisms by which this takes place, and to explain the relationship between osteoporosis and articular cartilage metabolism

🔖

Bu Makaleye Atıf Yap

ATBİNİCİ, H., SİPAHİOĞLU, S., AKSOY, N., BAYKARA, İ., IŞIKAN, U. E. (2015). Effects of salmon calcitonin treatment on serum and synovial fluid bone formation and resorption markers in osteoporosis patients. Acta Orthopaedica et Traumatologica Turcica, Cilt: 49 - Sayı: 2, 160–165. https://ajindex.com/articles/209829

Kaynakça (8)

  1. Miller PD, Zapalovski C. Bone mineral density measure- ments. In: Henderson JE, Goltzman D, editors. The osteo- porosis primer. Cambridge; New York: Cambridge Univer- sity Press; 2004. p. 262-77.
  2. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117-23.
  3. Lekkerkerker F, Kanis JA, Alsayed N, Bouvenot G, Burlet N, Cahall D, et al. Adherence to treatment of osteoporo- sis: a need for study. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporo- sis Foundation of the USA. 2007;18:1311-7.
  4. Christiansen C, Lindsay R. Estrogens, bone loss and pres- ervation. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Founda- tion of the USA. 1990;1:7-13.
  5. Faulkner KG, McClung MR. Quality control of DXA in- struments in multicenter trials. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 1995;5:218-27.
  6. Leggate J, Farish E, Fletcher CD, McIntosh W, Hart DM, Sommerville JM. Calcitonin and postmenopausal osteopo- rosis. Clin Endocrinol (Oxf ) 1984;20:85-92. Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Os- teoporosis international: a journal established as result of cooperation between the European Foundation for Osteo- porosis and the National Osteoporosis Foundation of the USA. 2000;11 Suppl 6:66-76.
  7. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporo- sis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2000;11 Suppl 6:2-17.
  8. Taguchi Y, Gorai I, Zhang MG, Chaki O, Nakayama M, Minaguchi H. Differences in bone resorption after meno- pause in Japanese women with normal or low bone mineral density: quantitation of urinary cross-linked N-telopep- tides. Calcif Tissue Int 1998;62:395-9. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized tri